Description
VACUTRO Tablets 97 mg + 103 mg TP (Pack of 28 Tablets)
High-Strength Dual Therapy for Chronic Heart Failure
VACUTRO Tablets combine Sacubitril 97 mg and Valsartan 103 mg in a single tablet, providing a potent therapeutic option for managing chronic heart failure (NYHA Class II–IV). This combination is part of the ARNI (Angiotensin Receptor–Neprilysin Inhibitor) class, proven to significantly reduce cardiovascular mortality and hospitalization rates in heart failure patients.
Sacubitril works by enhancing beneficial natriuretic peptides, promoting vasodilation and sodium excretion, while Valsartan blocks harmful angiotensin II effects, reducing blood pressure and cardiac stress.
Key Benefits:
-
Effective reduction in heart failure-related hospitalizations and mortality
-
Improves cardiac function and patient quality of life
-
Combines two mechanisms for comprehensive heart failure management
-
Convenient oral dosing, typically twice daily
Directions for Use:
Take as directed by your healthcare provider, usually twice daily with or without food.
Precautions:
Not recommended during pregnancy or concurrent use with ACE inhibitors. Regular monitoring of blood pressure, renal function, and serum potassium is advised.
Reviews
There are no reviews yet.